ADAM17 and cancer: There are indications that high concentrations of sPD-L1, together with high expression of ADAM10 (ADAM Metallopeptidase Domain 10) and ADAM17 (ADAM Metallopeptidase Domain 17) acted as predictors of poor response to immunotherapy in cancer patients [12].